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Abstract  
Neonatal chronic lung disease (nCLD) in preterm infants, also known as 
bronchopulmonary dysplasia (BPD) is one of the major complications arising in the 
premature infant. Pre- and postnatal stressors, such as mechanical ventilation (MV) 
and hyperoxia (O2) are known to contribute to disease development. In our study we 
observed that moderate prenatal cigarette smoke (pCS), enhances the vulnerability of 
the developing lung to postnatal injury resulting in impaired septation and vessel 
growth along with disturbed platelet drive growth factor (PDGF) signaling and 
extracellular matrix (ECM) remodeling.  
We hypothesized that pCS increases the development of adverse effects in response 
to postnatal injury (oxygen or mechanical ventilation) thereby impairing lung 
development in neonatal mice. The study specifically focused on histologic endpoints, 
i.e. the formation of alveoli and vessels in the face of altered growth factor signaling.  
Methods 
Female C57BL/6 (WT) and transgenig mice (8–10-weeks old) were exposed to CS 
from day 7 to day 18 of pregnancy. Smoke was generated from 3R4F Research 
Cigarettes (Tobacco Research Institute, University of Kentucky,Lexington, KY, 
U.S.A.). The chamber atmosphere was monitored to maintain 500 mg/m3 CS and mice 
were exposed to CS for 50 min twice per day. Control mice were kept in a filtered air 
(FA) environment. 5-8 days C57B6 (WT) mice from both groups (FA and pCS) either 
received mechanical ventilation (MV-O2), hyperoxia (O2; fiO2=0.4) or room air (RA; 
fiO2=0.21) for 8 hours. Lungs collected from these neonatal mice were subjected to 
histologic analysis including alveolar and micro-vessel number (20-100 µm), 
assessment of apoptosis (TUNEL and cleaved-caspase-3 staining) and immunoblot 
analysis for growth factors and vessel markers. PDGF-Rα haploinsufficient neonatal 
mice (Charles River) were subjected to the RA and hyperoxia model described above 
to unravel the potential role of the growth factor in this context. 
 
Results 
Without postnatal injury, neonatal mice that were exposed to pCS had decreased lung 
micro-vessel number alongside with increased apoptosis in endothelial cells, 
decreased VE-cadherin protein expression when compared to neonatal mice from the 
FA group. Alveolar number and size were not found to be different. When exposed to 
8h of hyperoxia alone or in combination with MV (MV-O2) micro-vessel number 
decreased further in neonatal mice from the pCS group together with increased 
apoptosis and significantly decreased expression of VE-cadherin and re-localization 
of elastic fibers. These results exceeded the effects observed in the FA animals. In 
addition, significant increase in the number of inflammatory cells, i.e. monocytes and 
neutrophils in the pCS group undergoing MV-O2 was observed when compared to FA 
group. 
The alveolar phenotype in the neonatal mice from the pCS group upon postnatal injury 
was PDGF-Rα dependent as shown by additional studies in transgenic mice. Here, 
alveolar size and number as well as septal density were further reduced when 
compared to WT mice following pCS. 
Conclusion 
We conclude that moderate pCS increases the vulnerability in neonatal mice to 
postnatal pulmonary injury as indicated by impaired alveolarization, micro-vessel 
formation and elastic fibers re-localization in these lungs. Furthermore, our data 
confirm the role of PDGF-Rα in postnatal lung pathology. 
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CHAPTER  
1. Introduction 
1.1 Bronchopulmonary dysplasia definition 
Neonatal Chronic Lung Disease (nCLD) is a long term respiratory problem in 
premature infants under 32 weeks of gestational age (GA) and/or with low birth weight 
<1500g [1, 2]. This disease is also commonly known as bronchopulmonary dysplasia 
(BPD). In neonatal intensive care, BPD is diagnosed at 36 weeks of GA. Criteria to 
diagnose BPD are pointed out by National Institute of Child Health and Human 
Development (NICHD) [3] (Table 1.). The grade of BPD severity is based on an 
assessment performed at 36 weeks postnatal day or 56 days of life if born after 32 
weeks: I) mild: room air (RA) at 36 weeks GA, II) moderate: <0.3 FiO2 at 36 weeks of 
GA and III) severe: >=0.3 FiO2 +/- positive pressure support at 36 weeks of GA [4]. 
Development of BPD is highly dependent on lung immaturity, as studies show the 
incidence of BPD is negatively correlated with GA and birth weight [5].  
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Table 1.1: BDP diagnosis criteria by NICHD(adapted from Jobe & Bancalari American 
Journal of Respiratory and Critical Care Medicine, 2001 [3]). These criteria are in 
addition to the baseline requirement of > 21% O2 for at least 28 days. Assesment at 
PMA or discharge whichever comes first. PMA = postmenstrual age 
1.2 Growth factor signaling in bronchopulmonary dysplasia 
pathophysiology 
Many of the premature infants without fully developed lungs need support for 
breathing. Mechanical ventilation with oxygen-rich gas (MV-O2) is a life-saving 
treatment for those infants in respiratory failure, however, this causes lung injury 
resulting in hypoalveolar septation and impaired angiogenesis. Clinical studies along 
with animal models characterized BPD by demonstrating impaired alveolarization with 
thickened alveolar septa, increased apoptosis and imbalanced growth factor signaling 
[6-8] . 
Growth factors regulating normal lung development include the platelet derived growth 
factor (PDGF). In the transition from the canalicular to the saccular and alveolar stage 
of lung development, PDGF-Rα expressing cells migrate to the secondary septal 
crests and drive alveolarization [9]. Previous studies showed that PDGF-A deficient 
mice fail to form alveoli due to failed migration of PDGF-Rα expressing cells to the tip 
of the secondary septal crests [10]. Furthermore, lungs of infants dying of BPD showed 
a decreased number of PDGF-Rα positive cells in the thickened septal crests [11]. 
1.3 Long-term outcome for BPD infants  
BPD infants are at risk for respiratory infections during infancy such as respiratory 
syncytial virus (RSV) and pneumonia as a result they are at a higher risk for re-
hospitalization than preterm infants without BPD [12].  
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1.4 Stages of lung development 
The lung is the onlyhighly organized organ of gas exchange in mammals. Lung 
development is highly dependent on interacition between a multitude of transcription 
factors, signalling molecules and more than 40 cell types to give rise to over 300 million 
alveoli and a complex capillary network [13]. 
Human and mice share some similarities in lung development. Mammalian lung 
development can be divided into five phases (Table 1.2, Figure 1.1) [14].  
1.4.1 Embryonic stage 
Formation of major airways arises from the primitive foregut endodermal epithelium in 
the embryonic stage of lung development [15]. 
1.4.2 Pseudoglandular stage 
The pseudoglandular stage is the most critical stage of the formation of conducting 
airways. Tubular branching and formation of the trachea that generates the bronchial 
tree occur in the fifth to seventeenth week of GA. Molecular signalling arises from 
interactions between mesenchymal-epithelial and alter cellular proliferation.  
1.4.3 Canalicular stage 
In the canalicular stage, blood tissue barriers for gas exchange emerge and form the 
pulmonary circulation, which results in dramatic changes in morphology. 
1.4.4 Saccular stage 
Interstitial tissue decreases in parallel to the increased capillary network, formation of 
alveolar walls and lamellar (site of storage surfactant) begin from about the twenty 
sixth GA until term. 
1.4.5 Alveolar stage 
In the Alveolar stage saccules continue to mature postnataly. A large number of ridges 
shape the airspaces and gas exchange surface area increases throughout the 
septation process and microvascular maturation arises [13, 16]. Moreover, elastic 
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fibres locate to the secondary crest to drive alveoarization that has been shown by 
PDGF-A in deficient mice models. 
 Stage Human (Weeks) Mouse (days)  
   Term 40 weeks Term 19 days 
Embryonic  3 – 7 9 - 12 
Pseudoglandular  5 - 17 12 - 16 
Canalicular  16 - 26 16 - 17 
Saccular  24 - 38 17 -PN 5 
Alveolar 36 - (1-2 years) PN 4 - 28 
Table 1.2: Timing of developmental phases in human and mouse lungs [14] 
 
Figure 1.1: Lung development in mice and humans. The five stages of lung 
development in mice and humans are displayed with corresponding the most 
important factors and time frame in each phase. E (Embryonic day), PN (Postnatal), 
Wk (Week) [15]. 
1.5 The lung structure  
The lung enables gas exchange, i.e. the transport of oxygen into the bloodstream and 
discharge of carbon dioxide out of the circulating blood into the atmosphere through 
alveolar-capillary membrane in the peripheral lung [17]. There are more than 300 
million alveoli forming this barrier in developed human lungs however at birth this 
number is less than 50 million [18]. This shows that the majority of alveolar formation 
occurs postnatally.  
Lung development is highly dependent on growth factor signaling. They are important 
mediators during organogenesis, including platelet-derived growth factor (PDGF), 
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vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) 
play a role as signaling molecules via tyrosine kinase receptors, stimulate cell 
proliferation, migration and differentiation in the developing lungs [19, 20].  
PDGF was originally discovered in 1974 by Ross et.al. as a growth factor stimuli for 
proliferation of mesenchymal cells. PDFG contains four ligands (PDGFA-D) and two 
receptors (alpha and beta) in both humans and mice. Animal studies have 
demonstrated the role of PDGF isoforms (PDGF-AA, PDGF-BB and PDGF-AB) in 
migration and proliferation of lung myofibroblasts through their high affinity receptors 
driving septation. Pre- and postnatal PDGFA/PDGF-Ra signaling is essential in 
alveogenesis [21]. 
VEGF is involved vasccularization in the alveolar epithelium during alveogenesis. 
Studies have shown reduction of VEGF expression in infants dying of BPD. Animal 
models of hyperoxia and MV-O2 applied to induce BPD, exhibited inhibited VEGF 
signalling accompanied with impaired alveolar and pulmonary micro-vascular 
formation [22-25]. 
TGF-β signalling pathways are essential for cellular proliferation, migration and 
differentiation. They are also involved in pulmonary morphogenesis, angiogenesis and 
embryonic development [26].  
1.6 Risk factors for BPD development 
BPD etiology is multifactorial. Pre- and postnatal risk factors have been identified by 
a multitude of clinical studies. Inflammation, impaired signalling and altered 
angiogenesis promote lung injury and development of BPD [27]. 
In the prenatal period, exogenous hazards such as amniotic infection or maternal 
smoking are known to predispose this patient cohort towards the development of 
adverse outcomes, the latter leading to intrauterine growth restriction (IUGR). 
Postnataly, mechanical ventilation and oxygen toxicity mainly account for the onset of 
nCLD in the neonates associated with impaired alveolar growth and disruption of 
angiogenesis in the developing lungs [28, 29].  
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1.6.1 Prenatal risk factors for BPD  
1.6.1.1 Maternal smoking as a cause of preterm birth 
Embryonic development is extremely susceptible to environmental changes and 
pollution. Cigarette smoke (CS) as an indoor pollutant affect maturation and is 
associate with neonatal chronic lung disease (nCLD) in preterm infants [30]. There are 
nearly 4000 damaging substances in CS, including nicotine and carbon monoxide 
(CO) [31]. These toxic components are carried to the fetus via the blood stream. It is 
well documented that maternal smoke exposure decreases growth factor expression 
in neonatal mice lung development, which has an impact on preterm delivery, fetal 
growth restriction and stillbirth [32]. 
Clinical studies confirm a dose dependent association of in utero CS exposure and an 
increase in risk of preterm delivery, bleeding during pregnancy, low birth weight and 
an adverse effect on lung development [33, 34] , yet, nearly one third of mothers 
smoke during some stage of their pregnancy in western countries [35]. CS is one of 
the risk factors associated with pulmonary disorders in the fetus and early postnatal 
life [36, 37]. Maternal smoking has a negative impact on vascular histopathology in the 
placenta causing fetal malnutrition and spontaneous preterm delivery mostly at the 
saccular stage of lung development [38]. Furthermore, CS elevates the stress 
hormone cortisol in amniotic fluid which initiates preterm labor in smoking mothers 
[39]. Many of these premature infants are at risk for developmental delays and chronic 
respiratory disease i.e. BPD [40]. The mechanism by which prenatal cigarette smoke 
(pCS) induces BPD is not fully understood. Animal studies have shown that pCS 
suppresses alveolar septation and pulmonary vascular development in pCS exposed 
mice [41]. Studies demonstrate maternal smoking increases susceptibility to develop 
asthma, which is shown in the HDM-induced mice model [42].  
1.6.1.2 Inflammation and BPD development 
There are a number of pathogens that can cause great damage to the fetus such as 
bacteria, viruses and parasites that are associated to development of fetal injury and 
death. It is known that infection cause 20-30% of preterm delivery [43]. Most preterm 
births associate with antenatal infection e.g. chorioamnionitis, which is a bacterial 
placental infection caused by Escherichia coli, mycoplasma hominis etc. leading to 
prenatal inflammation including neutrophilic infiltration in fetal membranes during 
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saccularization and alters cell signalling pathways critical in lung morphogenesis and 
vasculogenesis. This circumstance increases the risk of preterm birth and causes 
injury to the developing lung and brain [44, 45].  
1.6.2 Postnatal risk factors for BPD development 
1.6.2.1 Mechanical ventilation 
There are 10% of infants born prematurely with underdeveloped lungs. Many of those 
infants are in need of mechanical ventilation (MV). On one hand MV is life saving for 
preterm infants and on the other hand the positive pressure used in this process may 
lead to lung injury during saccualrization and alveolarization. Clinical studies 
demonstrates that around 30% of preterm infants develop BPD which, disrupts normal 
lung development and produces significant pulmonary and neurologic health 
consequences in this patient cohort [46]. In order to unravel the mechanism behind 
MV it is critical to understand the cellular and molecular mechanisms involved in lung 
development.  
Fibroblasts (FB) are essential cells for lung development and repair [47]. They are able 
to secrete cytokines to stimulate the healing inflammatary response; however, chronic 
inflammation can lead to lung injury [48]. During MV session endothelial cells (EC) and 
lung macrophages sense the mechanical stress and release proinflammatory 
cytokines that alters ECs to increase permeability in the alveolar-capillary resulting in 
protein leakage into the developing lungs and pulmonary edema [49, 50].  
A number of in vitro and in vivo studies demonstrate that signalling pathways regulate 
critical cellular functions in lung development. During alveolar formation sacules are 
subdivided by crests, forming a secondary septae location for myofibroblasts (MFB) 
and ECs to migrate to. Matrix proteins are secreted and enriched in elastin at the tip 
of the crests [51]. These stages in lung development are highly dependent on multiple 
signalling pathways that are disrupted by MV [52].  
1.6.2.2 Hyperoxia 
Supplemental oxygen is one of the factors responsible in disturbing lung development 
in preterm infants [53]. Immature lungs are unprepared for proper gas exchange. 
Therefore, to achieve decent oxygenation of blood, avoid tissue hypoxia and 
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respiratory diseases, administration of therapeutic oxygen is required in neonatal 
intensive care units [54]. Epithelium is the only tissue in the respiratory tract that is 
exposed to 21% oxygen which is very high compared to other tissues in the body [55]. 
Consequently, exposure to supplemental oxygen leads to oxygen induced injury 
(oxygen toxicity) in preterm infants [56].  
1.6.2.3 Infection  
Several clinical studies demonstrate the contribution of nosocomial infection with the 
risk of developing BDP. Nosocomial infections occur about 48 hours after birth, with 
non-maternal driven pathogens and in infants with very low birth weight who usually 
undergo extensive medical procedures [57]. 
1.7 Hypothesis  
We hypothesized that pCS increases the development of adverse effects in response 
to postnatal injury (oxygen or mechanical ventilation) thereby impairing lung 
development in neonatal mice.  
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2. Materials and Methods 
2.1 Study design 
Pregnant female mice were exposed to CS from day 7-18 of gestation (total 10 days 
of CS exposure) and control pregnant female mice were kept in a filtered air (FA) 
environment. After spontaneous delivery 5-8 day old neonatal mice were randomly 
selected from both pCS and FA group to undergo hyperoxia (40% O2) or mechanical 
ventilation with oxygen-rich gas (40% O2, MV-O2). Control group for pCS and FA were 
spontaneously breathed in room air (RA). 2-6 mice were utilized per group for 
histological analysis as well as 3-4 mice per group for protein analysis. Tissue sections 
from the respective mice lungs were selected randomly for histological analysis, 
immunohistochemistry, and immunofluorescence, as well as protein measurement 
and RNA analysis from frozen tissue. In vitro experiments were performed on 
myofibroblasts obtained from 3-9 different mice. 
2.2 Animals 
2.2.1 Ethics Statement 
All animal experiments were conducted under strict governmental and international 
guidelines under protocol 55.2-1-54-2531-117-10 and were approved by the local 
government for the administrative region of Upper Bavaria. 
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2.2.2 Animal maintenance 
For breeding, pathogen-free male and female C57BL/6 and transgenic mice were 
purchased from Charles River (Sulzfeld, Germany) and placed in rooms with constant 
temperature and humidity at a 12 h light cycle for 7 days before mating. Food and 
water were provided ad libitum for mice.  
2.2.3 Gene-targeted PDGF-Rα haploinsufficient (PDGF-Rα+/-) mice 
Gene-targeted heterozygous mice (B6.129S4-Pdgfra tm11(EGFP)Sor/J) were obtained 
from Jackson laboratories (Bar Harbor, Maine, USA). Heterozygous mice were healthy 
and was reported with no abnormal pulmonary phenotype [9]. For breeding, 
heterozygous male mice were mated with wild type (WT) female mice in order to avoid 
any effect of PDGF-Rα+/- i.e. perinatal lethality due to skeletal and pulmonary 
problems, on the course of the pregnancy [58]. Pre and postnataly, PDGF-Rα+/- and 
WT neonatal mice were subjected to the identical conditions. 
2.3 Prenatal Cigarette smoke (pCS) exposure experimental 
design  
CS was generated from 3R4F Research Cigarettes (Tobacco Research Institute, 
University of Kentucky, Lexington, KY). The filters from the research cigarettes were 
removed and cigarettes were burned within a modified TE-2 smoking machine 
(Teague Enterprise; Figure 2.1). Smoke was vaccumed into the exposure chamber by 
a membrane pump [59]. Pregnant female mice were whole body exposed to active 
100% mainstream CS of 500 mg/m3 for 50 min twice per day from day 7 to 18 of 
gestation for 10 days (Figure 2.2), where a pump switched between 2 s CS and 4 s air 
puff. Control mice were kept in a FA environment. After spontaneous delivery, pups 
were kept at room air with their mothers until the beginning of the experiment, i.e. 
postnatal day 5-8. 
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Figure 2.1: TE-2 smoking machine. (A) Research cigarettes 3R4F from the University 
of Kentucky, (B) animal chamber for cigarette smoke exposure, (C) TE-2 smoking 
machine (Teague Enterprise). 
 
Figure 2.2: Schematic representation of in utero cigarette smoke exposure. 8 to 10 
week old female pregnant mice were exposed to mainstream CS starting at gestational 
age (GA) of day 7 to 18 for 10 days. Fetuses were delivered naturally. 
2.4 Postnatal mechanical ventilation and hyperoxia exposure 
experimental design 
We employed 5-8 day old C57BL/6 neonatal mice, all born at term gestation with or 
without previous pCS exposure, that weighed 3.2 ± 0.5 g bw (FA) vs 3.4 ± 0.9 g bw 
(pCS), p= 0.2 to perform ventilation experiments in six groups of mice (3-6 mice per 
group): FA and pCS pups received MV-O2 or O2 for 8 h whereas respective controls 
spontaneously breathed RA for 8 h (Figure 2.3). Mice randomly selected from each 
litter to receive MV-O2. Tracheotomy was performed on each mouse after sedationwith 
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subcutaneous injections of ketamine (~60 µg/g , bw) and xylazine (~12 µg/g bw), 
followed by MV-O2 at 180 breaths/min from a customized, small animal respirator 
(MicroVent 848; Harvard Apparatus, Holliston, MA) for 8 h.  
Spontaneously breathing FA and pCS (RA and hyperoxia (O2) groups) received milder 
sedation with ketamine and xylazine (around one third of MV-O2 pups) for sham 
surgery (superficial neck incision). The ventilation protocol was designed to minimize 
lung injury typically occurring in response to MV with very high inflation pressures and 
O2. Therefore, we applied, modest tidal volumes (mean 8.7 µl/g bw, airway pressures: 
peak 12-13 cmH2O, mean 11-12 cmH2O, and limited the FiO2 to 40 %) imitating clinical 
settings for preterm infants with respiratory failure. The ventilation procedure has been 
described extensively by Bland et al [60]. A natural thermal environment was provided 
for the neonatal mice during MV-O2. Pups were sedated with ketamine and xylazine 
(10 µg/g bw, and 2 µg/g bw, respectively). The sedation was repeated to minimize 
spontaneous movement. PDGF-Rα+/- mice were subjected to O2 and RA under the 
same conditions as described above. At the end of each study, pups were euthanized 
with an intraperitoneal overdose of sodium pentobarbital, ~150 µg/g bw, and lungs 
were excised for various studies as described above (see 2.1). All animals were viable 
with response to tactile stimulation and adequate perfusion at the end of each 
experiment.  
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Figure 2.3: Postnatal injury experimental design. 5-8 day old neonatal mice were 
undergoing MV-O2 (left panel), spontaneously breathed O2 (middle panel) or 
spontaneously breathed RA (right panel) as control groups. 
2.5 In vivo experiments  
2.5.1 Histology  
2.5.1.1 Lung fixation and paraffin embedding  
Lungs from 8 h studies (n=3-6/group) were fixed intra-tracheally and were employed 
for quantitative histology, immunohistochemistry and immunofluorescence analysis. 
Tracheotomy was performed on sedated mice undergoing MV-O2 for 8 h, via insertion 
of a plastic catheter in trachea to inject 150 μl of 4% paraformaldehyde (PFA) to the 
lungs at 20 cmH2O pressure [60] for 16-18 h at 4 °C. By an excision in the thorax the 
lungs were removed and lung volume was measured (73 ± 10 μl in WT FA, 51 ± 14 μl 
in WT pCS, 77± 15 in PDGF-Rα+/- FA and 68 ± 16 in PDGF-Rα+/- pCS neonatal mice). 
The lungs were kept in 3 ml PFA at 4 °C for 16 h. Furthermore, the lungs were then 
prepared for embedding at the tissue processor machine (MICROM STP 42OD, 
Thermo Scientific) overnight where the lungs were incubated for, 1 h 70% ethanol, 1 
h 80% ethanol, 1 h 96% ethanol, 2x 2 h 96% ethanol, 1 h 100% ethanol, 2x 2 h 100% 
ethanol, 1 h xylene (Applichem Panreac, 131769.1612), continued with 3 h of 
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incubation in paraffin. For the embedding with paraffin 12 mm depth molds were used, 
lungs were placed in the center of the molds and filled with liquid paraffin until the 
lungs were submerged and the bottom of the embedding cassette were placed on the 
mold and kept on the cooling plate for 1 to 2 h. When the paraffin was solidified the 
block was taken out of the mold and kept at the room temperature.  
2.5.1.2 Isotopic Uniform Random orientation method (IUR) 
In the context of stereology and morphometric analysis we employed IUR technique. 
The paraffin blocks were separated from the cassette, an angel between 0-90° was 
randomly selected from a random number table. The block was placed on the IUR 
orientation sheet and oriented along its longitudinal axis, with the selected random 
angel along the 0o axis. This part of the block was cut by scalpel (Figure 2.4, red line). 
A random number was selected between 0-36°. The newly cut surface of the block 
oriented on the longitudinal axis with randomly selected angel. This angel was cut 
along 0o axis. A new surface was the side to be mounted into a brown mounting block 
holder to proceed for the sectioning. 
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Figure 2.4: Scheme of randomly oriented paraffin embedded block. The block was 
placed on the IUR orientation sheet with a pair of random numbers that was selected 
on the random number table. 
2.5.1.3 Sectioning the lungs 
Sectioning was accomplished by using a cutting apparatus called microtome (HYRAX 
M55, ZEISS). The microtome drives a knife across the surface of the paraffin block 
and produces a series of thin sections with uniform thicknesses. 12 sections were cut 
continuously and collected in a warm water bath of 45 °C. The thickness of the sections 
was adjusted to 4 μm for viewing with a light microscope. Two lung specimens were 
mounted on an individual microscope slide. Slides were placed on a heating plate for 
30 min at 40 °C. Between the intersections 10 sections were cut and discarded to 
randomize the sectioning.  
2.5.1.4 Haematoxylin and eosin stain 
Staining of histological sections allows observation of features otherwise not 
distinguishable. Haematoxylin and eosin (H&E) is the most commonly used stain to 
represent lung structure and morphometric analysis. Haematoxylin stains negatively 
charged structures, such as DNA, turning them blue in color. Eosin imparts a red color, 
it is used as counterstain to haematoxylin in H&E staining. 4 sections per animal (2-6 
animals per group) were randomly selected, deparaffinization was performed 
according to the following protocol: 2x 5 min xylene (Applichem Panreac, 
131769.1612), 2x 1 min 100% ethanol, 1 min 90% ethanol, 1 min 80% ethanol, 1 min 
70% ethanol, in the final step slides were washed for 30 s in dH2O. The staining of the 
fixed specimen was continued by the following protocol: 5 min incubation with Mayer‘s 
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Hämalaun (Roth, T865.1), rinsed with dH2O for 30 s, 10 s differentiation in HCL 
(Hydrochloric acid 32%, Roth, 9277.1) in 70% ethanol, 15 min rinsed under running 
tap water, 10 s rinsed in dH2O, 8 min incubated in 0.5% eosin (Roth, X883.1), followed 
by dehydrating the sections: 10 s 70% ethanol, 10 s 80% ethanol, 10 s 90% ethanol, 
2x 1 min 100% ethanol and 2x 5 min xylene. The slides were mounted by the mounting 
media (Entellan, Merck, 64271) under coverslips and kept under the hood overnight 
prior to imaging. 
2.5.1.5 Morphometric analysis of the lung sections 
Morphometric analysis of H&E slides were performed in BX51 Olympus light 
microscope with CAST-Grid 2.1.5 Olympus Software and Image J 1.47. Quantitative 
analysis of complete airspace surfaces (alveolar area), number of incomplete and 
complete alveolar walls (septal density), radial alveolar counts (≥ 30 fields of view 
(FOW)), the number of micro-vessels (20-100 μm diameter blood vessels) and 
atelectasis portion were quantitatively assessed in 2-3 independent random tissue 
sections per animal, 3-6 animals per group. Axio Imager Zeiss was employed to 
capture images (200X). 
2.5.1.6 Quantification of alveolar area 
BX51 Olympus light microscope was employed to quantify the alveolar area. The 
magnification of 200X was used for quantification of a total of 10 fields of view per 
section, 4 sections per animal. For this purpose CAST-Grid 2.1.5 software was applied 
to implement the surface of all complete airspaces.  
2.5.1.7 Quantification of alveoli and septal density 
BX51 Olympus light microscope was employed with 200X magnification. The number 
of alveoli with ≥ 30 fields of view were quantified in 2-3 independent random 4 μm H&E 
tissue sections per animal (CAST-Grid 2.1.5; Olympus). The quantification was 
performed as follows: a perpendicular line was drawn from the terminal bronchioles to 
the nearest pleura, the presence of complete alveoli along this line was counted, in 
contrast to complete alveoli, all alveolar septa that crossed the perpendicular line were 
counted and considered as septal density per field of view [18].  
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2.5.1.8 Quantification of micro-vessel  
MIRAX scanner was employed to scan the whole tissue specimen; the number of 
micro-vessels (20-100 μm) along with the number of complete alveoli were counted in 
10 fields of view per specimen with 400X magnification and normalized to 100 alveoli.  
2.5.1.9 Quantification of atelectasis  
Images from lung tissue specimen were captured by MIRAX scanner. Atelectasis area 
from 2 specimens per animal, 3-6 animals per group, was measured by Image J 
software with freehand line using 5X magnifications for the entire lung tissue surface 
and was normalized to the whole tissue area. Animals demonstrating more than 25% 
of atelectasis in the lung tissue were omitted from the quantification.  
2.5.2 Immunohistochemistry 
2.5.2.1 F4/80 (monocytes/macrophages) and Ly-6G (neutrophils)  
Lungs from 8 h studies (n=3–6/group) were deparaffinized as mentioned in section 
2.5.1.4. For immunohistochemistry, sections were incubated with peroxidase blocking 
reagent (Sigma, 31642) for 10 min, followed by incubation in normal goat serum for 1 
h, and next incubated with antibodies against specific antigens (in humidifying 
chamber overnight): rat anti-F4/80 (1:400, Abcam, ab 6640), rat anti-Ly-6G (Gr-1) 
(1:200, eBioscience, San Diego, CA, 16-9668). The slides were then incubated with 
biotinylated goat anti-rat secondary antibody (1:200, Santa Cruz Biotechnology, BA-
9400) for 1 h. Differentiation was performed using diaminobenzidine (DAB Kit, 
Invitrogen, 882014) for 1 min and counterstained with Mayer‘s Hämalaun (Roth, 
T865.1) for 30 s. The slides were dehydrated and mounted with the mounting media 
as mentioned above (see 2.5.1.4). 
Quantification 
Tissue stainig with F4/80 (monocytes/macrophages) and Ly-6G (neutrophils) was 
performed on 2 tissue sections per animal, 3 animals per group, and the slides were 
analyzed by counting the number of positively stained cells in 20 fields of view at 400X 
magnification and normalized to 100 alveoli. The complete alveoli were counted in the 
same field of view as the cells were counted.  
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2.6 TUNEL assay 
In order to visualize DNA fragments, the classical terminal deoxy-ribonucleotidyl 
transferase-mediated uridine 5′-triphosphate-biotin nick-end labeling (TUNEL) test 
was performed according to the manufacturer’s instructions (Millipore, ApopTag 
Peroxidase in Situ Apoptosis Detection Kit S7100). Deparaffinization was performed 
as mentioned above (see 2.5.1.4), followed by incubating in antigen retrieval (Sigma, 
31642) for 10 min, 0.5% Triton (Roth, 3051.2) in PBS for permeabilization for 10 min, 
slides were incubated with the terminal deoxynucleotidyle transferase-labeled 
nucleotide mixture at 37 °C for 60 min in the dark before converter-peroxidase solution 
(POD) was added to the samples (30 min, 37 °C). After incubation with 
diaminobenzidine substrate (10 min, 15–25 °C), slides were counterstained with 
haematoxylin for 1 min. The slides were dehydrated and mounted as mentioned above 
(see 2.5.1.4). 
Quantification 
2 tissue sections per animal, 3-4 animals per group were stained with TUNEL assay. 
BIOQUANT LIFE SCIENCE software was employed to analyze the stained sections 
in 10 field of view per animal with 400X magnification, by using a consistent expression 
threshold which was quantified total surface area (lung tissue), apoptotic area (stained 
by TUNEL assay) and normalized to whole tissue area. 
2.7 Hart’s stain 
Demonstration of elastic fibers in the lung tissue was performed by Hart’s elastic stain. 
Lungs from 8 h studies (n=3–6/group) were deparaffinized as described above (see 
2.5.1.4). The slides were incubated in 0.25% potassium permangagate (Merck 
1.05082) for 5 min, rinsed with dH2O, dipped in 5% oxal acid (Sigma, 247537) for 10 
s, rinsed with tap water, and incubated with Resorcinol fuchsine solution (Weigert, 
Roth X877.1) overnight in darkness at room temperature. Following incubation, the 
slides were rinsed with tap water for 15 min, incubated with 0.25% tartazine (Sigma, 
86310) for 90 s. The slides were then dehydrated and mounted as mentioned above 
(see 2.5.1.4). 
Quantification 
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2 tissue sections per animal, 3-6 animals per group were stained by Hart’s. 
BIOQUANT LIFE SCIENCE software was employed to analyze the stained sections 
in 10 field of view per animal with 400X magnification, by using a consistent expression 
threshold which was quantified total surface area (lung tissue), and elastic fibers that 
were differentiated into dark brown to black color and normalized to whole tissue area.  
2.8 Immunofluorescence (IF) 
2.8.1 PDGF-Rα, VE-cadherin and cleaved caspase-3 IF stain 
Immunofluorescence staining was performed in lung tissue sections from 2-6 animals 
per group. The slides were deparaffinized as described above (see 2.5.1.4) placed in 
0.1 M citrate buffer, pH 6.0 and placed into a Decloaking Chamber for 30 s at 125 °C 
for 10 s at 90 °C. The tissue sections were permeabilized with 0.5% triton (Roth, 
3051.2) in tris buffer for 10 min and rinsed 3X with tris buffer before antibody 
incubation: PDGF-Rα (C-20, Santa Cruz Biotechnology, 338), VE-Cadherin (H-72, 
Santa Cruz Biotechnology, 28644), cleaved caspase-3 (Cell Signalling Technology, 
9661) at 4 °C overnight. The following day the slides were washed 3X5 min with tris. 
Primary antibody detection was done with an Alexa 488/568—labeled donkey anti-
goat antibody (Life technologies, A1105/A11057) for 30 min at room temperature in 
darkness, washed 3X 5 min with tris. Visualization as well as mounting was performed 
with fluorescence mounting medium (Dako, North America, S3023). 
Quantification 
2 tissue sections per animal, 2-6 animals per group were analyzed in BITPLANE 
Imaris x64 9.0.0 by counting the number of single or double positive cells in 20 fields 
of view at 400X magnification and normalized to 100 nuclei. The images were captured 
by AXIO imager confocal microscope. 
2.9 Protein analysis 
2.9.1 Protein extraction  
Lungs from neonatal mice were admitted to 8 h studies (n=3-4/group) were excised 
and snap-frozen in liquid N2, and stored at -80 °C for later protein extraction. Protein 
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extraction was performed as follows: lungs were cut into small pieces, placed in 
eppendorf tubes, 600 μl of extraction buffer (contained 11 ml of high urea buffer; a 
mixture of 0.139 g HK2PO4, 12 g urea and 35 ml of dH2O (KPO4, Urea, AppliChem, 
Darmstadt, Germany) and 110 μl Halt Protease Inhibitor Cocktail (Thermo Fisher 
Scientific, 1861280). The lung tissue was homogenized by dismembrator (IKA T10, 
Ultra Turrax) and incubated for 1 h at 4 °C, then centrifuged at 14000 g for 30 min at 
4 °C, supernatant (protein) was collected and kept at -80 °C. 
2.9.2 Determination of protein concentration bicinichonic acid (BCA) 
assay 
Protein concentration measurement was performed using the bicinchoninic acid (BCA) 
assay (Pierce Scientific Rockford, IL, USA, 23227) according to the manufacturer’s 
instructions.  
2.9.3 Protein detection via western blot analysis 
For protein separation a NuPAGE (Life Technologies, 4-12% Bis-Tris, NPO321box) 
polyacrylamide gel electrophoresis was employed. 35 µg protein of each sample in a 
total volume of 20 µL and 40 µL was loaded to 4-12% Bis-Tris. Gel electrophoresis 
was performed in 1x running buffer for 55 min at 200 V. Nitrocellulose membranes 
(Life Technologies, LC2006) were incubated for 10 min in the transfer buffer prior to 
protein transfer. Proteins were transferred to the membranes for 1 h at 30 V in 1x 
transfer buffer. After blocking of the membranes with 5% skim milk (Sigma Aldrich, 
70166) in 0,1% TBS-T for 1 h at room temperature, the membranes were incubated 
with the following antibodies at 4 °C overnight: PDGF-Rα (C-20, Santa Cruz 
Biotechnology, 338, 1:1000), VEGF-A (147, Santa Cruz Biotechnology, 507, 1:200), 
VE-Cadherin (H-72, Santa Cruz Biotechnology, 28644, 1:1000), SMAD2/3 (Cell 
Signaling Technologies, 3102, 1:1000), pSMAD2 (Cell Signaling Technologies, 3101, 
1:1000), CYP1A1 (A-9, Santa Cruz Biotechnology, SC-393979, 1:1000), SPARC 
(D10F10, Cell Signaling Technologies, 8725, 1:1000), JAK-2 (Cell Signaling 
Technologies, 3230, 1:1000) and STAT-3 (Cell Signaling Technologies, 9139, 
1:1000). 
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After overnight incubation, the membrane was washed 3x with TBS-T and incubated 
with HRP-coupled secondary antibody of goat anti-rabbit IgG (Santa Cruz 
Biotechnology, 2301, 1:5000) and goat anti-mouse IgG (Santa Cruz Biotechnology, 
2060, 1:5000) for 1-2 h at 4 °C. Other washing steps were performed (3x with TBS-T). 
As an internal loading control, membranes were stripped and re-probed with 1:5000 
dilution of a mouse monoclonal anti-β-actin antibody (Santa Cruz Biotechnology, sc-
81178) followed by 1:5000 dilution of goat anti-mouse IgG-HRP (Santa Cruz 
Biotechnology, 2060). For the visualization of the protein bands 2 ml of detection 
reagents chemiluminescence ECL prime Detection Kit (GE Healthcare, 
Buckinghamshire, Great Britain, RPN2232) was applied. Chemical conversion of 
substrate was recorded with a Chemidoc XRS system. Quantification of band 
intensities was calculated with the Image Lab software v4.01 and normalized to β-
actin (loading control, Santa Cruz Biotechnology, 81178, 1:5000).  
2.10 RNA Isolation 
Lung tissue was homogenized using a dismembrator machine (IKA T10, Ultra Turrax). 
For total RNA isolation the RNA Kit (peqGOLD Safety-line, 732-2870) was used 
according to the manufacturer’s protocol.  
2.11 RNA concentration 
RNA concentration was determined by measuring the absorbance at 260 nm in 
nanodrop (ND-100, NanoDrop Technologies). According to the Beer-Lambert law and 
using the extinction coefficient of RNA (0.025 (μg/ml)-1 cm-1) a reading of 1.0 
(absorption at 260 nm) is equivalent to 40 μg/ml single stranded RNA. 
2.12 Reverse transcription of mRNA 
For the reverse transcription of RNA, 1 µg of RNA was applied to total volume of 20 µl 
with RNase/DNase-free water at 70 °C for 10 min in thermomixer. Denatured RNA 
was stored for 5 min on ice. For each samples 20 µl of the master mix was prepared 
as follows: 4 µl of 10x PCR buffer (Applied Biosystems, 4376212) 2, 8 µl MgCl2 
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(Applied Biosystems, 3613912) (25mmol/L), 2 µl dNTP’s (Thermo scientific, R0192) 
(10 mmol/L), 2 µl Random Hexamer (Applied Biosystems, 58002113-01) and Reverse 
Transcriptase (Applied Biosystems, 58002112-01), 1 µl of RNase inhibitor (10U, 
Applied Biosystems, 58002110-1), 20 μl of RNA template and 1 µl of RNase/DNase-
free water. Pipetted into 0.5 ml tube and centrifuged for 10 s. The condition for reverse 
transcription included 10 min at 20 °C, 75 min at 43 °C, 5 min at 99 °C and cooled 
down at 4 °C. In addition, 140 µl of RNase/DNase-free water was added in each 
sample to adjust the volume to 160 µl. cDNA was stored at -20 °C. 
Quantitative real time RT-PCR 
mRNA expression of target gene MCP-1 in comparison to house keeping control 
hypoxanthine-guanine phosphoribosyltransferase (HPRT)-1 was determined using 
Platinum SYBR Green qPCR SuperMix (Roche, 18887320) on a LightCycler 480 II 
(Roche). Primer sequences (Eurofins mwg operon, Ebersberg, Germany) were used 
for MCP1 (forward 5’- CTT CTG GGC CTG CTG TTC A -3’, reverse 5’- CCA GCC 
TAC TCA TTG GGA TCA-3’) and HPRT-1 (forward 5’- CCT AAG ATG AGC GCA AGT 
TGA A -3’, reverse 5’- CCA CAG GAC TAG AAC ACC TGC TAA -3’). Relative 
transcript expression of a gene is given as 2−ΔCT (ΔCt = Cttarget – Ctreference), relative 
changes compared to control are 2−ΔΔCt values (ΔΔCt = ΔCttreated– ΔCtcontrol). Primers 
were generated using Primer-BLAST software. 
2.13 In vitro experiments 
2.13.1 Mouse primary pulmonary myofibroblasts 
5-8 day old C57BL/6 mice were sacrificed by IP injection of pentobarbital (150 μg/g 
bw). The lungs were excised, cut into small pieces (1mm) and incubated for 15-20 min 
at 37 °C and cultured in media at 37 °C (Gibco, 41966-029) with Pen/Strep (Gibco, 
15140-122) and Gentamycin (Lonza, BE02-012E, Basel, Switzerland) until confluence 
of 80-85%. The media was changed every 48 hours. Cells were characterized 
previusely in our group for fibroblasts markers [61].  
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2.13.2 Preparation of CS extract (CSE)  
Stocks of CS were prepared by bubbling smoke directly from six 3R4F research-grade 
cigarettes (filters on)(Tobacco and Health Research Institute, University of Kentucky, 
Lexington, KY, USA) through 100 ml of phenol-red free cell culture media (Gibco, 
17005-034) as described in Van Rijt S.H. et al [62]. 
2.13.3 CS exposed myofibroblasts 
Myofibroblasts were seeded into 96-well plates at a cell density of 1.5 × 103 cells per 
well, the plates were kept at 37 °C with 5% CO2 overnight. On the following day, culture 
media with 0.5% CSE was added to the cells (80-85% confluent). The cells were 
treated in the absence of the test compound were the negative control. After incubated 
for 12 and 24 h, 100 μl of Cell Titer-Glo reagent (Promega, G757) was added to 100 
μl of medium containing cells. The plate was incubated for 10 min at room 
temperature. Luminescence acquired on Berthold multimode microplate reader LB 
941 (Berthold Technologies GmbH, Germany). 
2.14 Statistical Analysis  
Statistical analysis was performed using Prism 6 software (GraphPad, San Diego, 
CA). For analysis of results derived from in vivo experiments investigating the impact 
of two or more study variables, e.g. pCS, postnatal injury or genotype two-way analysis 
of variance (ANOVA) with Bonferroni correction was performed. When comparing only 
two groups/parameters (e.g. in vitro), student’s unpaired t-test with Welche’s 
correction was chosen. Results were given a mean and standard deviation (SD) n-
number is depicted in the figure legends. 
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CHAPTER   
3. Results  
3.1 Non growth-restricting doses of prenatal CS regulate 
smoke-dependent proteins in the neonatal lung 
We established a mouse model exposing pregnant mice to pCS (500 mg/m3 CS, 50 
min, twice a day, from day 7 to day 18 of pregnancy for 10 days), to investigate the 
effect of pCS on lung development in mice. The model was designed to avoid induction 
of growth restriction in the neonatal mice. Body weight (bw) of the mothers at the end 
of the pregnancy is comparable between the treatment groups (25 ± 1.4 g bw (FA) vs 
25 ± 1.8 g bw (pCS) p = 0.3). Likewise, bw of the newborns at the beginning of the 
experiment is not significantly different (3.2 ± 0.5 g bw (FA, WT) vs 3.4 ± 0.9 g bw 
(pCS, WT), p= 0.2, (Figure 3.1 A); 3.3 ± 0.6 g bw (FA, PDGF-Rα+/-) vs 3.0 ± 0.4 g bw 
(pCS, PDGF-Rα+/-), p= 0.9). 
In order to demonstrate the regulation of proteins indicating the impact of CS [63] in 
the lung of neonatal mice exposed to pCS, we measured protein levels of cytochrome 
P450 1A1 (CYP1A1) and secreted protein acidic and rich in cysteine (SPARC) in total 
lung homogenates. In accordance with studies in adult mice undergoing CS, neonatal 
mice exposed to pCS show a significant increase in lung CYP1A1 whereas the 
pulmonary levels of SPARC are significantly downregulated when compared to FA 
mice (Figure 3.1 B- C).  
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Figure 3.1: Comparable body weights of pCS and FA treated mice at the beginning 
of the study rule out the presence of growth retardation due to pCS exposure. (B-C) 
Immunoblot analysis demonstrates a significant increase of CYP1A1 (B) and a 
decrease in SPARC (C) protein levels in total lung homogenates of neonatal mice 
undergoing pCS when compared to FA mice. Data are presented as mean ±SD. 
*p<0.05, **p<0.01, n=3-6 mice/group, * vs respective RA controls. 
3.2 Alterations of pulmonary inflammation in response to 
prenatal cigarette smoke (pCS) 
In order to investigate inflammatory response to prenatally exposed neonatal mice to 
CS, we detected the presence of neutrophils and monocytes/macrophages in those 
lungs. 
3.2.1 Exposure to prenatal CS leads to increased influx of inflammatory 
cells in the lung of neonatal mice 
The application of pCS increases the presence of neutrophils, monocytes and their 
inflammatory mediators in the lungs of neonatal mice when compared to FA group 
(Figure 3.2 A-E).  
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Figure 3.2: Representative immunohistochemistry of lung tissue sections (400X) from 
5-8 day old mice showing Ly-6G and F4/80 indicating increased number of pulmonary 
neutrophils and macrophages/monocytes (orange) respectively in pCS mice (A, C, 
lower panel, black arrows) when compared to FA controls (A, C, upper panel, black 
arrows). Quantitative analysis of positively stained number of pulmonary Ly-6G and 
F4/80 normalized to 100 alveoli per field of view confirm a significant increase of 
neutrophil and monocyte number in the lungs of neonatal mice after pCS (B, D). (E) 
mRNA analysis demonstrating increased lung MCP-1 expression in pCS mice when 
compared to FA controls. The data shown here is normalized to HPRT.Data are 
presented as mean ±SD. *p<0.05, n=3-6 mice/group,* vs respective RA controls. 
Quantitative analysis in A and C is performed in 10 fields of view per section in a total 
of 2 sections per animal. 
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3.3 Apoptosis in the lung of neonatal mice exposed to pCS 
To determine whether pCS exposure to neonatal mice may impair lung growth and is 
a major contributing factor to the development of bronchopulmonary dysplasia, we 
investigated the apoptosis in the lung of neonatal mice. 
3.3.1 Prenatal CS exposure increases apoptosis in the lung of neonatal 
mice  
Immunoblot analysis showed a significant increase in pSMAD-2 protein expression in 
the lungs of pCS mice when compared to FA pups (Figure 3.3 A) along with the 
increased inflammatory response. As a result of this, we detected a significant 
induction of apoptosis in the lung periphery of neonatal mice that underwent pCS 
(more than 50% increase) when compared to neonatal mice from the FA group (Figure 
3.3 B-E).  
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Figure 3.3: Immunoblot analysis showing an induction of phosphorylated Smad-2, 
normalized to total SMAD2-3 expression (β-actin as loading control) in total lung 
homogenates of neonatal mice after pCS when compared with FA control. (B-C) 
Representative TUNEL staining of lung tissue sections (400X) from 5-8 day old mice 
showing increased apoptosis (brown) in pCS mice (B, lower panel, black arrows) when 
compared to FA group (B, upper panel, black arrows). The ratio of apoptotice area to 
the whole tissue area confirm increased apoptosis upon pCS exposure (C). (D-E) 
Representative immunofluorescence staining of lung tissue sections (400X) from 5-8 
day old pups demonstrating increased apoptosis (cleaved caspase-3, green) in pCS 
neonatal mice (D, lower panel, white arrows) when compared to FA mice (D, upper 
panel, white arrows) DAPI (blue nuclei). Quantitative analysis of cleaveds caspase-3+ 
cells normalized to 100 nuclei per field of view confirm increased apoptotic nuclei 
(cleaved caspase-3, green, white arrows) upon pCS exposure (E). Data are presented 
as mean ±SD. **p<0.01, n=3-6 mice/group,* vs respective RA controls. Quantitative 
analysis in B and D is performed in 10 fields of view per section in a total of 2 sections 
per animal. 
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3.4 In utero CS exposure disrupts lung development 
Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) play a critical 
role in cell proliferation, differentiation and migration furthermore, PDGF signaling is 
crucial for organ development such as eye, kidney, and lung. To investigate whether 
pCS impairs PDGF signaling, we studied expression of PDGF in parallel with lung 
morphometry and elastic fibers deposition in the lung of pCS neonatal mice. 
3.4.1 Prenatal CS exposure leads to apoptosis in PDGF-Rα positive cells 
in the lungs of neonatal mice  
Quantitative analysis of dual immunostaining for lung apoptosis reveals a significant 
increase in apoptotic PDGF-Rα expressing cells (Figure 3.4 A-B) consistent with a 
decrease in the total number of PDGF-Rα positive cells (Figure 3.4 C-D) in the lungs 
of pCS mice when compared to FA controls. Immunoblot analysis from lung tissue 
homogenates show a significant reduction of PDGF-Rα protein expression in the lung 
of pCS neonatal mice (Figure 3.4 E) supporting the results from differential tissue stain 
analysis.  
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Figure 3.4: Representative immunofluorescent staining of lung tissue sections (400X) 
from 5-8 day old mice shows an increased number of PDGF-Rα (red) and 
cleavedcaspase-3 (green) double positive cells (orange) (normalized to 100 nuclei per 
field of view) in pCS mice (A, lower panel, white arrows) when compared to FA group 
(A, upper panel, white arrows) DAPI (blue nuclei). Quantitative analysis of double 
positive PDGF-Rα and cleaveds caspase-3 cells normalized to 100 nuclei per field of 
view confirm increased apoptosis in PDGF-Rα positive cells pCS mice (B). (C-D) 
Representative immunofluorescent staining of lung tissue sections (400X) from 5-8 
day old pups revealing decreased number of PDGF-Rα positive cells (red) (normalized 
to 100 nuclei per field of view) in pCS mice (C, lower panel, white arrows) when 
compared to FA (C, upper panel, white arrows). Quantitative analysis of PDGF-Rα+ 
cells normalized to 100 nuclei per field of view show reduction of PDGF-Rα positive 
cells in pCS mice (D). (E) Immunoblot analysis shows a significant downregulation in 
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PDGF-Rα protein levels in both FA and pCS treated neonatal mice total lung 
homogenized demonstrates reduction of PDGF-Ra protein expression in pCS mice 
when compared to FA group. Data are presented as mean±SD. *p<0.05, **p<0.01, 
n=3-6 mice/group, * vs respective RA controls. Quantitative analysis in A and C are 
performed in 10 field of view per section in a total of 2 sections per animal. 
3.5 Impaired septation and altered elastin deposition observed 
in the lung of pCS exposed neonatal mice 
As PDGF-Rα positive cells, also known as lung myofibroblasts are driving alveolar 
septation and elastin production in the alveolar compartment of the developing lung, 
we addressed both processes in our analyses. 
Histologic analysis from differential tissue staining of the lung of neonatal mice, 
demonstrate a significant reduction in the number of pulmonary septal crests in pCS 
exposed mice when compared to FA (Figure 3.5 A), whereas alveolar size and number 
(Figure 3.5 B-C) as well as lung volume measured by fluid displacement (pCS 
0.68±0.1 µl/g bw vs FA 0.54±0.06 µl/g bw, p=0.7) are not different between the groups. 
Hart’s stained lung tissue sections visualizing elastic fibers were assessed for the 
amount and distribution of elastic fibers in the lung periphery. The results demonstrate 
a significant increase in the area covered by elastic fibers in the lungs of pCS mice 
when compared to FA controls (Figure 3.5 E). Qualitative image analysis shows 
redistribution of the elastic fibers in the alveolar region present in mice that underwent 
pCS in contrast to their positioning at the tip of the septal crests in FA mice (Figure 3.5 
D).  
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Figure 3.5: Quantitative histologic analysis of lung tissue sections demonstrates a 
reduced number of secondary septi by counting the number of incomplete alveolar 
walls crossing perpendicular line normalized to 100 alveoli per field of view in mouse 
lungs following pCS when compared to FA.(D-E) however, the alveolar size (complete 
airspace surfaces) and number (number of complete alveoli along perpendicular line 
normalized to 100 alveoli per field of view) did not show any significant differnces in 
the pups exposed to pCS in comparision to their FA group (B-C). Representative 
Hart’s staining of lung tissue sections (400X) from 5-8 day old pups indicating 
increased amount of elastin (brown to black fibers) deposited in the lung periphery in 
pCS mouse lungs (D, lower panel, black arrows) compared to FA mice (D, upper 
panel, black arrows). Qualitatively, the elastic fibers are re-arranged in mouse lungs 
after pCS and localized alongside the alveolar walls in contrast to lungs from FA mice, 
where elastin is found at the tip of the septal crests (black arrows). Quantitative 
analysis revealing increased deposition of elastic fibers in pCS mice (E). Data are 
presented as mean±SD. *p<0.05, **p<0.01, n=3-6 mice/group, * vs respective RA 
controls. Quantitative analysis in D is performed in 10 field of view per section in a total 
of 2 sections per animal. 
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3.6 Exposure to prenatal CS provokes endothelial cell 
apoptosis resulting in loss of lung micro-vessels 
Immunofluorescence double staining for the micro-vessel marker VE-cadherin and 
cleaved-caspase-3 demonstrates a significant increase of pulmonary endothelial cell 
apoptosis in neonatal mice underwent pCS followed by decreased number of VE-
cadherin positive cells (Figure 3.6 A-D). This finding is confirmed by immunoblot 
analysis of lung tissue homogenates revealing a significant reduction of lung VE-
cadherin in neonatal mice exposed to pCS as compared to FA group (Figure 3.6 E). 
As a consequence, histological analysis from differential lung tissue staining shows a 
significant reduced number of pulmonary micro-vessels (20-100 μm) in the lungs of 
pCS neonatal mice when compared to FA pups (Figure 3.6 F).  
As vascular endothelial growth factor (VEGF)-A is a main regulator of endothelial cell 
survival; we employed immunoblot analysis for VEGF-A protein levels in order to 
address potential upstream causes of our findings. We show aA significant reduction 
in lung VEGF-A protein levels in pCS mice when compared to FA controls (Figure 3.6 
G). This reduction of VEGF-A expression could be attributed to impaired PDGF-Rα 
down-stream signaling in response to pCS, i.e. decreased protein levels for JAK-
2/STAT-3 [64, 65] (Figure 3.6 H-I). 
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Figure 3.6: Representative immunofluorescent staining of lung tissue sections (400X) 
from 5-8 day old neonatal mice showing an increased number of VE-cadherin (red) 
and cleavedcaspase-3 (green) double positive cells (orange) (normalized to 100 nuclei 
per field of view) in pCS mice (A, lower panel, white arrows) when compared to FA 
group (A, upper panel, white arrows) DAPI (blue nuclei). Quantitative analysis 
confirming increased apoptosis in VE-cadherin positive cells pCS pups (B). (C-D) 
Representative immunofluorescent staining of lung tissue sections (400X) from 5-8 
day old pups revealing decreased number of VE-cadherin positive cells (red) 
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(normalized to 100 nuclei per field of view) in pCS mice (C, lower panel, white arrows) 
when compared to FA (C, upper panel, white arrows) DAPI (blue nuclei). Quantitative 
analysis showing reduction of VE-cadherin positive cells in pCS group (D). (E) 
Immunoblot analysis for VE-Cadherin confirms reduced protein expression in total 
lung homogenates from pCS mice in contrast to FA mice. (F) Histologic analysis 
reveals a significant decrease in the number of micro-vessels (20-100µm diameter) 
per field of view (normalized to 100 alveoli) in the lungs of neonatal mice undergoing 
pCS when compared to FA controls. (G) Immunoblot analysis of total lung 
homogenates for VEGF-A, regulating endothelial cell survival, showing reduction of 
protein level normalized to β-actin (loading control) in pCS treated neonatal lungs 
when compared to FA mice. (H-I) Immunoblot analysis of total lung homogenates for 
JAK-2 (H) and STAT-3 (I) revealing significant reduction of protein levels normalized 
to β-actin in pCS mice when compared to FA control. Data are presented as mean 
±SD. *p<0.05, **p<0.01, ***p<0.001, n=3-6 mice/group, * vs respective RA controls. 
Quantitative analysis in A and C are performed in 10 field of view per section in a total 
of 2 sections per animal. 
3.7 Exposure of neonatal mice to postnatal injury as hyperoxia 
(O2) or MV with oxygen rich gas (MV-O2) 
3.7.1 Aggravated inflammatory response upon postnatal exposure to 
MV-O2 in the lungs of pCS treated neonatal mice 
Presence of monocytes/macrophagges in the pulmonary tissue representing of lung 
tissue inflammation that further increases upon postnatal injury, i.e. exposure to O2 
and MV-O2 for 8 h in pCS mice. In contrast, monocyte infiltration in the lungs of FA 
neonatal mice did not change (Figure 3.7 A-B). Our mRNA analysis reveale increased 
lung MCP-1 expression in pCS mice followed by O2 and MV-O2 when compared to FA 
pups (Figure 3.7 C). The data shown here is normalized to HPRT. The number of 
neutrophils was significantly elevated in both groups upon O2 and MV-O2 (Figure 3.7 
D-E).  
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Figure 3.7: Representative immunohistochemistry for F4/80 of lung tissue 
sections(400X) from 5-8 day old mice undergoing postnatal O2 or MV-O2 for 8h 
indicating further increase in number of the macrophages/monocytes (orange) in pCS 
mouse lungs (A, lower panel, black arrows), thereby significantly exceeding the effect 
in FA (A,upper panel, black arrows). Quantitative analysis of pulmonary F4/80 stained 
cells normalized to 100 alveoli per field of view confirm a significant increase of 
macrophages/monocytes number in the lungs of neonatal mice upon pCS (B). (C) 
mRNA analysis confirms a significant increase in MCP-1 mRNA expression in lungs 
from pCS mice with postnatal injury, i.e. exposure to O2 or MV-O2 when compared to 
FA pups. The data shown here is normalized to HPRT. (D-E) Representative 
immunohistochemistry for Ly-6G of lung tissue sections (400X) from 5-8 day old mice 
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undergoing postnatal O2 or MV-O2 for 8h indicating further increase in number of the 
neutrophils (orange) upon postnatal injury in both pCS (D, lower panel, black arrows), 
and FA (D,upper panel, black arrows) when compared to their RA control. Quantitative 
analysis of pulmonary Ly-6G stained cells normalized to 100 alveoli per field of view 
confirm a significant increase of neutrophils number in the lungs of neonatal mice 
undergoing postnatal injury (E). Data are presented as mean ±SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, n=3-6 mice/group, * vs respective RA controls, § vs 
respective O2, # vs respective MV-O2 Quantitative analysis in A and D are performed 
in 10 fields of view per section in a total of 2 sections per animal.  
3.7.2 Induction of apoptosis in the lungs of pCS treated neonatal mice 
upon postnatal exposure to O2 and MV-O2  
pCS increases the sensitivity of the neonatal lung in response to postnatal O2 or MV-
O2 exposure by significantly increase apoptosis when compared to FA mice (Figure 
3.8 A-B, C-D).  
 
Figure 3.8: Representative TUNEL staining of lung tissue sections (400X) from 5-8 
day old mice indicating increased apoptosis (brown) upon postnatal O2 and MV-O2 in 
pCS mice (A, left panel, black arrows) when compared to FA group (A, right panel, 
black arrows). The ratio of apoptotice area to the whole tissue area confirm increased 
apoptosis upon postnatal O2 and MV-O2 in pCS mice exceeding the effect in the FA 
(B). (C-D) Representative immunofluorescent staining images of lung tissue sections 
(400X) from 5-8 day old pups followed by postnatal O2 and MV-O2 demonstrating 
increased apoptosis (cleaved caspase-3, green) in pCS neonatal mice (C, lower panel, 
white arrows) when compared to FA group (C, upper panel, white arrows) DAPI (blue 
nuclei). Quantitative analysis of cleaved caspase-3+ cells normalized to 100 nuclei per 
field of viewconfirm increased apoptotic nuclei upon postnatal O2 and MV-O2 in pCS 
exposed pups (D). Data are presented as mean ±SD. **p<0.01, ***p<0.001, 
****p<0.0001, n=3-6 mice/group, * vs respective RA controls, § vs respective O2, # vs 
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respective MV-O2 Quantitative analysis in A and C are performed in 10 fields of view 
per section in a total of 2 sections per animal. 
3.7.3 Septation defect in the lungs of neonatal mice exposed to pCS 
followed by postnatal O2 and MV-O2 
Upon postnatal O2 or MV-O2, lung morphometry (Figure 3.9 A) reveals an increase in 
airspace size and a decrease in alveolar number within neonatal mice following pCS 
and FA (Figure 3.9 B-C). In contrast, an aggravated reduction in the number of 
secondary septa is observed in the lungs of pCS exposed mice when compared to FA 
(Figure 3.9 D).  
 
Figure 3.9: Representative lung tissue H&E sections (200X) from 5-8 day old mice 
undergoing postnatal O2 or MV- O2 for 8h. Lungs from both groups, pCS (A, lower 
panel) as well as FA (A, upper panel) exhibited larger and fewer alveoli after postnatal 
injury. Nonetheless, septal density appeared to be less in the prenatal smoke mice 
undergoing postnatal injury. (B-D) Quantitative histologic analysis of lung tissue 
sections confirmed the presence of larger and fewer alveoli in the lungs of neonatal 
mice undergoing 8h of O2 or MV- O2 regardless of prenatal exposure to pCS or FA (B, 
C). Nonetheless, mice that underwent pCS showed less secondary septai when 
exposed to postnatal injury (D). Data are presented as mean ±SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, n=3-6 mice/group, * vs respective RA controls, § vs 
respective O2, # vs respective MV- O2 Quantitative analysis in A is performed in 10 
fields of view per section in a total of 4 sections per animal. 
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3.7.4 Diminished PDGF-Rα positive cells in the lungs of neonatal mice 
exposed to pCS followed by O2 and MV-O2  
Lung of pCS exposed neonatal mice undergoing postnatal injury show a significant 
reduction in septal density that is associated with a significant decrease in the number 
of PDGF-Rα positive cells when compared to FA pups (Figure 3.10 A-D).  
 
Figure 3.10: Representative immunofluorescent staining images of lung tissue 
sections (400X) from 5-8 day old pups followed by postnatal O2 and MV-O2 
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demonstrating increased apoptosis (cleaved caspase-3, green) in pCS neonatal mice 
(A, lower panel, white arrows) when compared to FA group (A, upper panel, white 
arrows) DAPI (blue nuclei). Quantitative analysis of cleaved caspase-3+ cells 
normalized to 100 nuclei per field of viewconfirm increased apoptotic nuclei upon 
postnatal O2 and MV-O2 in pCS exposed pups (B). (C-D) Representative 
immunofluorescent staining of lung tissue sections (400X) from 5-8 day old mice 
shows an increased number of PDGF-Rα (red) and cleaved caspase-3 (green) double 
positive cells (orange) (normalized to 100 nuclei per field of view) upon postnatal O2 
and MV-O2 in pCS mice (C, lower panel, white arrows) when compared to FA group 
(C, upper panel, white arrows) DAPI (blue nuclei). Quantitative analysis of double 
positive PDGF-Rα and cleaved caspase-3 cells normalized to 100 nuclei per field of 
view confirm increased apoptosis of PDGF-Rα positive cells in pCS mice upon 
postnatal O2 or MV-O2 (D). Data are presented as mean ±SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, n=3-6 mice/group, * vs respective RA controls, § vs 
respective O2, # vs respective MV-O2 Quantitative analysis in A and C are performed 
in 10 fields of view per section in a total of 2 sections per animal.  
3.7.5 Increased apoptosis in lung endothelial cells in neonatal mice 
exposed to pCS followed by postnatal O2 and MV-O2  
The alveolar pathology in pCS mice undergoing postnatal O2 and MV-O2 is followed 
by an increased loss of alveolar micro-vessel when compared to FA pups (Figure 3.11 
C). These changes result from a significantly greater pulmonary endothelial cell 
apoptosis in mice following pCS and subsequent postnatal lung injury when compared 
to the changes in the FA group (Figure 3.11 A-B).  
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Figure 3.11: Representative immunofluorescent staining of lung tissue sections 
(400X) from 5-8 day old pups demonstrating increasing number of VE-cadherin (red) 
and cleaved caspase-3 (green) double positive cells (orange) (normalized to 100 
nuclei per field of view) upon postnatal O2 and MV-O2 in pCS mice (A, lower panel, 
white arrows) when compared to FA group (A, upper panel, white arrows) DAPI (blue 
nuclei). Quantitative analysis of double positive VE-cadherin and cleaved caspase-3 
cells normalized to 100 nuclei per field of view reveal increased apoptosis of VE-
cadherin positive cells in pCS mice upon postnatal O2 or MV-O2 (B). (C) Quantitative 
histologic analysis of lung tissue sections confirms an increased loss micro-vessels 
(20-100µm diamete) (per field of view, normalized to 100 alveoli) in the lungs of 
neonatal pCS mice undergoing postnatal O2 and MV-O2 when compared to FA mice. 
Data are presented as mean ±SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3-
6 mice/group, * vs respective RA controls, § vs respective O2, # vs respective MV-O2. 
Quantitative analysis in A is performed in 10 fields of view per section in a total of 2 
sections per animal. 
3.8 PDGF-Rα haploinsufficiency (PDGF-Rα+/-) drives lung 
pathology induced by pCS 
To elucidate whether PDGF signaling is inadvertently related to the lung pathology 
induced by pCS, we challenged a transgenic mouse model with pCS and postnatal 
lung injury. As shown by studies in mice and humans, PDGF-Rα expressing cells drive 
alveolarization and thereby hold a role in BPD pathophysiology [66, 67]. In our model, 
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different pathophysiologic characteristics observed are related to PDGF signaling 
including impaired septation and altered elastin deposition.  
3.8.1 Aggravated inflammatory response in the lungs of PDGF-Rα+/- 
neonatal mice exposed to pCS 
Presence of monocytes/macrophagges in the pulmonary tissue representing of lung 
tissue inflammation that further increases upon postnatal injury, i.e. exposure to O2 for 
8 h in pCS exposed PDGF-Rα+/- neonatal mice, in compare with WT pups (Figure 3.12 
A-B). 
 
Figure 3.12: Staining of representative lung tissue sections (400X) from 5-8 day old 
PDGF-Rα haploinsufficient mice undergoing postnatal O2 for 8h for F4/80 indicating 
macrophages/monocytes (orange). Lungs from pCS mice (A, lower panel, black 
arrows) demonstrated a larger number of macrophages/monocytes when compared 
to FA group (A, upper panel, black arrows). (B) This inflammatory response 
significantly increased after postnatal injury in the lungs of PDGF-Rα+/- neonatal mice 
exposed to pCS followed by 8h O2 in contrast to FA pups. Quantitative analysis of the 
number of pulmonary F4/80 stained cells per field of view, normalized to 100 alveoli in 
lung tissue sections (400X) confirm a significant increase of monocytes in the lungs of 
PDGF-Rα+/- neonatal mice undergoing 8h O2 after pCS. Data are presented as mean 
±SD. ***p<0.001, ****p<0.0001, n=2-6 mice/group, ϕ vs RA PDGF-Rα+/-, ¤ vs O2 
PDGF-Rα+/-. Data are presented as mean ±SD. ***p<0.001, ****p<0.0001, n=2-6 
mice/group, ϕ vs RA PDGF-Rα+/-, ¤ vs O2 PDGF-Rα+/-. Quantitative analysis in A is 
performed in 10 fields of view per section in a total of 2 sections per animal. 
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3.8.2 Lung morphometry in pCS exposed PDGF-Rα+/- neonatal mice 
followed by O2  
Causally relating PDGF signaling to lung pathology observed following pCS, we show 
that the exposure of PDGF-Rα+/- neonatal mice to pCS aggravates the alveolar 
phenotype observed in WT mice with fewer alveoli at 5-8 days of age. The number of 
alveoli and secondary septi in the lung of pCS exposed PDGF-Rα+/- mice undergoing 
postnatal O2 further reduces when compared with FA mice (Figure 3.13 A-B).  
Hart’s stained lung tissue sections visualizing mature elastic fibers demonstrate a 
significant decrease of elastic fibers deposition in the lungs of pCS exposed PDGF-
Rα+/- pups when compared to WT mice (Figure 3.13 C-D).  
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Figure 3.13: For quantitative histologic analysis of lung tissue sections using the 
number of complete alveolar walls per field of view, normalized to 100 alveoli show a 
reduced number of alveoli in the lungs of PDGF-Rα+/- pCS mice when compared to 
WT pCS pups this reduction of alveoli is aggravated upon postnatal exposure to O2 in 
PDGF-Rα+/- neonatal mice (A). (B) for quantification of secondary crests applying the 
number of incomplete alveolar walls normalized to 100 alveoli per field of view reveal 
enhanced loss of septa in the lungs of neonatal pCS treated PDGF-Rα+/- mice 
undergoing postnatal O2 exposure when compared to WT pups. (C-D) Representative 
Hart’s staining of lung tissue sections (400X) from 5-8 day old pups indicating 
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reduction of elastic fiber deposition (brown to black fibers) in the lung periphery of 
PDGF-Rα+/- neonatal mice (C, lower panel, black arrow) compared to WT group (C, 
upper panel, black arrows). Qualitatively, the elastic fibers are re-arranged in mouse 
lungs after pCS and localized alongside the alveolar walls in contrast to lungs from FA 
mice, where elastin is found at the tip of the septal crests (black arrows). Quantitative 
analysis revealing decreased deposition of elastic fibers in PDGF-Rα+/- of pCS 
exposed mice undergoing O2 (D). Data are presented as mean ±SD. *p<0.05, 
***p<0.001, ****p<0.0001, n=2-6 mice/group, * vs respective RA controls, ϕ vs RA 
PDGF-Rα+/-, ¤ vs O2 PDGF-Rα+/-. Quantitative analysis in C is performed in 10 fields 
of view per section in a total of 2 sections per animal. 
3.8.3 Increased apoptosis in lung endothelial cells in PDGF-Rα+/- 
neonatal mice exposed to pCS 
Dual immunostaining for VE-cadherin and cleaved-caspase-3 reveals a significant 
increase of pulmonary endothelial cell apoptosis in neonatal PDGF-Rα+/- mice 
exposed to pCS and a consecutive decrease of VE-cadherin positive cells when 
compared to WT mice following pCS. This effect is enhanced in both groups exposed 
to O2, with the effect in PDGF-Rα+/- mice exceeds the effect in WT pups (Figure 3.14 
A-D). 
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Figure 3.14: Representative immunofluorescent staining of lung tissue sections 
(400X) from 5-8 day old mice shows an increased number of VE-cadherin (red) and 
cleaved caspase-3 (green) double positive cells (orange) (normalized to 100 nuclei 
per field of view) upon postnatal O2 and in PDGF-Rα+/- neonatal mice exposed to pCS 
(A, lower panel, white arrows) when compared to WT pups (A, upper panel, white 
arrows) DAPI (blue nuclei). For quantitative analysis using the number of double 
positive VE-cadherin and cleaved caspase-3 cells normalized to 100 nuclei per field of 
view confirm increased apoptosis of VE-cadherin positive cells in pCS mice upon 
postnatal O2 (B). (C-D) Representative immunofluorescent staining images of lung 
tissue sections (400X) from 5-8 day old pups followed by postnatal O2 demonstrating 
decreased number of VE-cadherin positive cells (normalized to 100 nuclei per field of 
view) in pCS exposed PDGF-Rα+/- neonatal mice (C, lower panel, white arrows) when 
compared to WT group (C, upper panel, white arrows) DAPI (blue nuclei). For 
quantitative analysis applying the number of VE-cadherin+ cells normalized to 100 
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nuclei per field of view reveal reduction of VE-cadherin positive cells in PDGF-Rα+/- 
neonatal mice exposed to pCS (D). Data are presented as mean ±SD. *p<0.05, 
**p<0.01, ***p<0.001, n=2-6 mice/group, ϕ vs RA PDGF-Rα+/-, ¤ vs O2 PDGF-Rα+/-. 
Quantitative analysis in B and D are done by 10 field of view per section in a total of 2 
sections per animal. 
3.9 In vitro CS exposure reduces the survival of primary lung 
fibroblasts 
In vitro, we demonstrate the effect of smoke extracts on the survival of primary lung 
fibroblasts expressing PDGF-Rα, showing that the application of 0.5% CS extract 
proves a time -dependent effect of CS on reduced viability of PDGF-Rα lung fibroblasts 
(Figure 3.15 A-B). This experiment was done in colaboration with Prajakta Oak and 
Markus Koschlig. 
 
Figure 3.15: Significant decrease in viability upon 12 h (A) and 24 h (B) treatment with 
0.5% CS extract in primary neonatal mouse lung fibroblasts as compared to untreated 
cells. Data are presented as mean ±SD. **p<0.01, n=4 cell lines, * vs control. 
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3.10 Summary of the study 
 
Figure 3.16: Schematic overview over the pulmonary effects in pCS-exposed 
neonatal mice undergoing postnatal injury. pCS exposure of pregnant mice (day 7-18 
of gestation) provokes a significant influx of monocytes/macrophages into the 
developing neonatal lung investigated at day 5-8 of life. This effect is enhanced by the 
exposure of these neonates to mechanical ventilation (MV-O2), resulting in an increase 
of apoptosis in PDGF-Rα positive myofibroblasts (MFB). Subsequently, lung structur 
revelas alveolar growth arrest with decreased septation and re-localisation of elastic 
fibers. Associated with MFB apoptosis, lung VEGF-A levels are decreased together 
with an increase in endothelial cells (ECs) apoptosis and a loss of lung micro-vessels.
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CHAPTER  
4. Discussion  
In neonates, the risk for the development of nCLD and impaired long-term pulmonary 
outcome associated with pCS exposure points out the significant clinical relevance of 
this condition [68, 69]. Yet, deeper mechanistic insight into this disease 
pathophysiology still remains elusive as clinical and experimental studies often do not 
allow the distinguish between the impact of CS and other pre- and postnatal risk 
factors with respect to nCLD development.  
To elucidate whether and how pCS hinders lung development, we avoided the 
presence of growth restriction. We developed a preclinical mouse model to study the 
unique effect of moderate pCS on lung development and its impact on pulmonary 
vulnerability to postnatal injury as well as the central mechanism driving the observed 
pathology. 
4.1 CS exposure protocol  
In order to understand the adverse effect of pCS exposure on lung development, 
several animal models were established, which were varied in type, term and dose of 
exposure. The type of exposure was split among passive smoking [70], active smoking 
[71] , or nicotine as an alternative for CS [72]. 
Regarding terms of exposure; preconceptual [71], prenatal [73] and postnatal [74] 
exposure has been employed during life span stages. Moreover, the dose of exposure 
is very different in order of times and number of cigarettes per day. In most models, 
such as neonatal rhesus monkeys and mice confirming smaller and less compliant 
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lungs resulting from prenatal exposure to nicotine alone and CS, respectively [75, 76]. 
These findings are in line with studies revealing long term adverse consequences in 
adult mice after prenatal exposure to CS [76]. In humans, abnormal airway walls in 
infants from smoking mothers [77] matched the findings in mice, where maternal 
smoke exposure increased the susceptibility to airway hyperreactivity [78]. Despite 
some knowledge gained by these studies, the outlined models have significant 
limitations. The CS exposure regimen used in pregnant mice mirrors standard regimen 
used in adult mice but provoke intra-uterine growth restriction in most cases [76, 78]. 
These studies make it uneasy to determine between the direct effect of pCS on lung 
development and the effect mitigated through impaired intrauterine growth [79].  
4.2 Influence of pCS as prenatal injury in neonatal mice lungs 
As mentioned earlier, embryogenesis is the first stage in lung development and 
expands during the first 2 years of postnatal life. Moreover, alveogenesis continues up 
to 15 years after birth. In utero, CS exposure leads to stillbirth or preterm delivery to 
low birth weight infants. Many studies demonstrate the adverse effect of in utero CS 
and nicotine exposure on developing lungs by disrupted lung growth, impaired immune 
balance and increased susceptibility of the lungs towards infections in children with 
CLD [80].  
Our study is based on non-growth restricting doses of CS during pregnancy to avoid 
growth retardation in the neonatal mice. However, this study shows increase 
inflammation and apoptosis in the neonatal lungs resulting in the loss of septi and 
small vessels in pCS exposed neonatal mice. Furthermore, the study can directly 
relate the observed pathology to the impact of pCS and recapitulates the main findings 
from studies in adult mice where the onset of CLD in CS exposure results from the 
induction of a severe inflammatory response leading to airway remodeling and airflow 
limitation, accompanied by an emphysematous phenotype with larger and fewer 
alveoli as seen in chronic obstructive pulmonary disease (COPD) [81, 82]. 
4.2.1 Presense of smoke dependent protein in pCS neonatal mice lungs 
It has been proposed in the literature that cytochrome P450 1A1 (CYP1A1) protein 
expression is upregulated in human placenta, newborn rat lungs and liver upon CS 
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[83]. We also demonstrat upregulation of CYP1A1 in the lung of neonatal mice 
exposed to pCS. This proves the permability of placenta in humans and those animal 
models. 
4.2.2 Inflammatory response and apoptosis in the lungs of pCS exposed 
neonatal mice 
Many studies have focused on pulmonary inflammatory response in adult lungs with 
long term CS exposuer which leads to emphysema and COPD [84]. Our study reveals 
high influx of pulmonary monocytes/macrophages in parallele with over expression of 
pSMAD-2 in the lung of pCS exposed mice. The predominance of a monocyte-
centered inflammatory response in our model not only points towards the role of the 
pulmonary monocyte in particle defense [85] but at the same time underlines its role 
in matrix remodeling [86], further perpetuating the inflammatory response.  
Additionaly, interauterin CS exposure increases apoptosis in these lungs. Apoptosis 
usually takes place during lung organogenesis and injury [87]. The activation of the 
TGF-β pathway upon monocyte infilteration is well-known for its role in the 
development of BPD [88]. This illustrates the significant increase of lung apoptosis 
observed in pCS exposed neonatal mice. Studies show that caspases are regulatory 
apoptosis proteases and caspase-3 plays a role in the initiationof cell apoptosis. 
Ahmed et. al 2013 show increased activity of caspase-3 and decreased cell 
proliferationin in fetal rat lungs [89]. Consistent with this study, we demonstrate 
increasing number of cleaved caspase-3 positive cells in pCS exposed mice lung. This 
denotes the cleavage of procaspase-3 to active caspase-3 which is detected in 
immunoflorecence lung tissue stain. 
4.2.3 Loss of septi and micro-vessels in the lung of pCS exposed 
neonatal mice 
It is well documented that nicotine freely passes through the placenta and 
concentrates in the amniotic fluid [90]. Studies on mice show increased proliferation 
of undifferentiated embryonic stem cells (ESC) in nicotine exposed induced pluripotent 
stem (iPS) cells [91]. Furthermore, Yehudah et al shows downregulation of specific 
genes involved to ESC differentiation into fibroblasts of in utero CS exposed 
nonhuman primate lungs. The study indicates exposure to nicotine during 
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embryogenesis impairs ESC differentiation into fibroblasts [80, 92]. Fibroblasts are 
critical components in lung development. In lung injury fibroblasts differentiate into 
secreting myofibroblasts to repair injured locations. It has recently been shown that 
myofibroblasts (MFB) are mostly located in areas with constant remodeling in 
response to stress [93]. They are known for secretion matrix molecules into interstitial 
space as well as secreting growth factors i.e. PDGF and VEGF. Moreover PDGF-Rα 
positive cells, also referred to as lung myofibroblasts, are known to drive alveolar 
septation and elastin production in the alveolar compartment of the developing lung. 
A decline in the number of PDGF-Rα positive cells in the lungs of pCS exposed 
neonatal mice shed light on the lack of pulmonary septal crests and remodeled matrix 
in our study.  
Previous studies show impaired septation in the lung of VEGF deficient mice indicating 
VEGF as an important key role in alveolar formation [94] .  
In line with the loss of PDGF-Rα positive cells we observe a significant increase of 
pulmonary endothelial cell apoptosis in the lungs exposed to pCS. Reduction of VEGF-
A protein level, a main regulator of endothelial cell survival attributes to impaired 
PDGF-Rα down-stream signaling a response to pCS.  
4.3 The role of O2 and MV-O2 as postnatal injury in pCS 
exposed neonatal mice lungs 
In order to study the potential of pCS to induce pulmonary vulnerability towards 
postnatal injury, we combined the mouse model of prenatal smoke exposure with a 
unique, preclinical model of mechanical ventilation and hyperoxia in neonatal mice. 
The model has been shown to lead to the development of a BPD like phenotype [95]. 
Indeed, the postnatal exposure to MV-O2 or even moderate hyperoxia was able to 
enhance the changes observed in the lungs of pCS mice with the effects exceeding 
postnatal injury in FA treated mice, indicating the increased susceptibility to injury in 
these lungs.  
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4.3.1 Increased susceptibility to postnatal injury in the lung of pCS 
exposed neonatal mice 
Mechanical ventilation is a lifesaving therapy for patients with acute respiratory failure. 
However, in the present study MV-O2 or/and moderate O2 of preinjured lungs 
exaggerated the influx of monocytes/macrophages in the pulmonary tissue, reflecting 
respiratory compliance and elastic fibers properties. In line with the increase of 
inflammation in pCS lungs, greater apoptosis along with an aggravated loss of septal 
crests and pulmonary capillaries upon MV-O2 and O2 indicative of increased 
susceptibility in those lungs towards postnatal injury in our study. 
4.4 The effect of pCS on PDGF-Rα haploinsufficient (PDGF-
Rα+/-) neonatal mice lungs 
Studies show PDGF-A and PDGF-Rα are highly expressed in the developing mice 
embryo. Boström et al demonstrate critical role of PDGF-A in the developing lung, 
leading to MFBs differentiation and alveolar formation which is completely blocked in 
the PDGF-A deficient mouse model [21]. Furthermore, the fact that half of PDGF-A 
deficient embryos typically die before E10 led us to employ PDGF-Rα haploinsufficient 
(PDGF-Rα+/-) neonatal mice that express the half of PDGF-Rα and have no phynotypic 
difference with wildtype pups.  
4.4.1 Lung pathology induced by pCS in PDGF-Rα+/- neonatal mice 
Deprivation of pulmonary PDGF-Rα fibroblasts along with the loss of secondary septi 
upon pCS exposure, led us to further investigate the role of PDGF signaling in pCS 
induced lung pathology. By using transgenic mice, we related the crucial role of the 
PDGF receptor in the induction of pCS pathophysiology, in line with its predominant 
role in lung development and disease [4, 66]. Previuos studies have demonstrated the 
contribution of MFBs promote ECM depositon and drive alveolarization displaying an 
effective role in BPD pathophsiology [66, 86]. In the current study all observed different 
pathophysiologic characteristics are linked to PDGF signaling including impaired 
septation, altered elastin deposition and impaired vascularization in neonatal PDGF-
Rα+/- mice exposed to pCS. This effect is further enhanced upon postnatal O2 
exposure. 
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4.5 In vitro study of smoke effect on PDGF-Rα positive cells 
While it is well established that high levels of CS have an adverse effect on cell viability 
and leads to cell death, the effect of moderate CS on cell survival is not well 
understood. Clinical studies demonstrate that smokers suffer from impaired wound 
healing and have a tendency to develop fibrotic diseases [96]. Further studies show 
CS treated fibroblasts decrease cell migration and increased cell adhesion and 
thereby delays the healing process. In this study we analized the effect of different 
time points of CS exposure on the viability of the pulmonary PDGF-Rα positive cells 
in vitro. Further investigation in our study, unravels the loss of survival in PDGF-Rα 
positive cells upon CS exposure within different time points.  
4.6 Conclusions 
The molecular mechanisms underlying the pathophysiology of BPD are complex. 
Understanding the role of each factor that contributes to development of BPD will 
provide the basis for understanding the molecular physiology of this disorder. CS is 
one of the risk factors for preterm delivery, leads to low birth weight and development 
of BPD. To truly mirror the multifactorial conditions contributing to human BPD we 
developed our study model that aims to combine multiple factors that closely match 
already addressed clinical issues in BPD. 
Taken together, our study demonstrates the characteristics of pulmonary injury 
provoked by pCS exposure using a unique, preclinical model. The valuable insight into 
the injury mechanism driving the lung phenotype in pCS provides a candidate for 
future treatment options, as PDGF signaling plays a central role in disease 
pathophysiology.
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7. Abbreviations 
 
Abbreviation Description 
ANOVA  Analysis of variance 
BPD  Bronchopulmonary dysplasia 
bw Body weight 
cDNA Complementary 
CO Carbon monoxide 
COPD Chronic obstractive pulmonary disease 
CS Cigarette smoke 
CYP1-A1 Cytochrome P450 1A1  
DAPI 4 ,6-diamidino-2-phenylindole 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxy-Nucleotide-Tri-Phosphate 
EC Endothelial cell 
ECM  Extracellular matrix 
FA Filter air 
FB Fibroblast 
GA Gestational age  
h Hour 
HRP Horseraddish peroxidase 
IUGR  Intrauterine growth restriction  
IUR Isotopic uniform random orientation  
kDa Kilodalton 
MCP-1 Monocyte chemoattractant protein-1 
MFB Myofibroblast 
min Minute 
mRNA Messenger ribonucleic acid 
MV Mechanical ventilation 
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